Dan Leonard
Stock Analyst at UBS
(3.83)
# 702
Out of 4,996 analysts
300
Total ratings
53.61%
Success rate
7.95%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Buy | $70 → $80 | $60.03 | +33.27% | 10 | Sep 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $11.72 | +10.92% | 6 | Aug 8, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $53.57 | -1.06% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $11.80 | +27.12% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $496.79 | -38.61% | 2 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $460 → $500 | $464.24 | +7.70% | 17 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Buy | $240 → $225 | $184.84 | +21.73% | 18 | Jul 23, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $185 → $225 | $179.56 | +25.31% | 16 | Jul 23, 2025 | |
| MTD Mettler-Toledo International | Upgrades: Buy | $1,530 → $1,350 | $1,204.43 | +12.09% | 9 | May 20, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $95 → $70 | $51.84 | +35.03% | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $57 → $45 | $31.04 | +44.97% | 11 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $271.36 | +14.24% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $269.90 | +14.86% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $84.06 | +36.81% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $92.72 | +6.77% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.84 | +111.15% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $148.56 | +24.53% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $9.20 | -2.17% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $22.59 | +54.94% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $123.39 | +21.57% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $91.69 | +118.13% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.82 | +290.07% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $162.97 | -57.05% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $13.22 | -47.05% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $291.71 | +18.27% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $163.79 | +58.74% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $188.99 | -23.28% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $67.21 | +33.91% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $43.90 | +44.99% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $280.61 | +21.16% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $25.66 | -6.47% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $7.70 | +354.55% | 12 | Aug 14, 2019 |
Guardant Health
Sep 25, 2025
Maintains: Buy
Price Target: $70 → $80
Current: $60.03
Upside: +33.27%
10x Genomics
Aug 8, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $11.72
Upside: +10.92%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $53.57
Upside: -1.06%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $11.80
Upside: +27.12%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $496.79
Upside: -38.61%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Neutral
Price Target: $460 → $500
Current: $464.24
Upside: +7.70%
Danaher
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $184.84
Upside: +21.73%
IQVIA Holdings
Jul 23, 2025
Maintains: Buy
Price Target: $185 → $225
Current: $179.56
Upside: +25.31%
Mettler-Toledo International
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,204.43
Upside: +12.09%
Bio-Techne
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $51.84
Upside: +35.03%
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $31.04
Upside: +44.97%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $271.36
Upside: +14.24%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $269.90
Upside: +14.86%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $84.06
Upside: +36.81%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $92.72
Upside: +6.77%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.84
Upside: +111.15%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $148.56
Upside: +24.53%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $9.20
Upside: -2.17%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $22.59
Upside: +54.94%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $123.39
Upside: +21.57%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $91.69
Upside: +118.13%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.82
Upside: +290.07%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $162.97
Upside: -57.05%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $13.22
Upside: -47.05%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $291.71
Upside: +18.27%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $163.79
Upside: +58.74%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $188.99
Upside: -23.28%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $67.21
Upside: +33.91%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $43.90
Upside: +44.99%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $280.61
Upside: +21.16%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $25.66
Upside: -6.47%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $7.70
Upside: +354.55%